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Protein quality control is essential for cellular homeostasis, and defects in the same result 
in various pathological conditions such as neurodegenerative diseases and cancer. 
Amyotrophic lateral sclerosis (ALS) is one such condition, involving the degeneration of 
motor neurons in the central nervous system. Misfolded mutant Superoxide dismutase 1 
(SOD1) protein and its aggregates are a hall mark of 15-20% of ALS cases involving 
hereditary linkage. While several therapeutic strategies, ranging from small molecules to 
antisense oligonucleotides, have been examined, Riluzole is the only candidate to receive 
FDA approval for treatment. The purpose of this study is to explore the effect of 
upregulating p53-mediated transcription as a viable therapeutic strategy. Two compounds 
were chosen to do so. The study shows that both compounds enhance locomotor activity 
in SOD1G93A mice, suggesting possible therapeutic applications. Furthermore, one of the 
compounds reduced the amount of mutant SOD1 aggregates both in vitro and in vivo 
suggesting its role in the clearance of misfolded proteins. Although neither of the 
compounds increased life span, they may be used in conjunction with other molecules, 
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Amyotrophic Lateral Sclerosis (ALS; also known as ‘Lou Gherig’s disease’ or ‘motor 
neuron disease’) is a progressive degenerative disorder involving atrophy of upper and 
lower motor neurons in the brain and spinal cord, eventually leading to paralysis followed 
by death caused by denervation of respiratory muscles, an event that occurs upon five years 
of diagnosis. Having an annual incidence of 1-2.6 and prevalence of 6 cases per 100,000 
individuals respectively coupled with an average age of onset being 58-60 years(Talbott, 
Malek, & Lacomis, 2016), ALS may be considered the most frequent of the rare 
neurological diseases. However, its uniform lethality imparts an importance out of 
proportion with its incidence. 
 
Despite the vast amount of literature available, the exact pathophysiology of ALS remains 
unknown. Several genetic factors have influenced our understanding of the disease. 10-
20% of all ALS cases have been transmitted through families in an autosomal dominant, 
autosomal recessive or X-linked manner, and is termed as familial ALS (FALS). However, 
80-90% of the cases show no distinct genetic linkage and are termed sporadic ALS 
(SALS)(Corcia et al., 2017). 
 
The first gene implicated in ALS was mapped to the Cu/Zn Superoxide dismutase 1 
(SOD1) locus after the assessment of several families. Upon identifying 13 disease causing 
mutations, they attributed mutant SOD1 to be the cause of 15-20% of all FALS cases, and 




causing mutations have been elucidated with the list continuously growing. An updated list 
for the same may be found at http://alsod.iop.kcl.ac.uk/.  
 
SOD1 is a 153 amino acid cytosolic protein that is ubiquitously expressed in all cell types. 
It functions as a homodimer which binds two copper and two zinc atoms (one of each per 
monomer) and partakes in redox chemistry within the cell. It functions to neutralize the 
superoxide anion (a by-product of oxidative phosphorylation) by converting it to hydrogen 
peroxide via cyclical oxidation and reduction of copper (dismutation). SOD1 spans across 
five exons, all of which can contain disease causing missense mutations. While most 
mutations reduce enzymatic activity, some disease causing (e.g. SOD1G93A) ones have no 
effect on catalysis. This adds to the pre-existing perplexion that none of the mutations are 
indicative of disease progression and clinical co-relation(Kiernan et al., 2011). However, 
it has been established that most variants of SOD1 cause ALS in all populations. SOD1A4V 
has been identified as the most frequent disease causing one in continental United States 
resulting in it being one of the most studied genotypes. As a result, the current hypotheses 
suggest a combination of loss-of-function and gain-on-function mechanisms that 
contribute to the disease.  
 
Post-mortem studies have fueled two primary hypotheses for SOD1-ALS. The initial 
hypothesis, which fueled the discovery of SOD1-ALS, is that oxidative stress in catalysis 
deficient motor neurons cause apoptosis. A gain of toxicity mechanism was elucidated on 
the discovery of SOD1 aggregates when overexpressing wild type SOD1 while co-




deficiencies in protein folding or degradation challenged the pre-existing oxidative stress 
hypothesis. Several other links suggesting the involvement of aberrant mRNA 
processing(Yasuda et al., 2017) , glutamate cytotoxicity, altered autophagy and 
nucleocytoplasmic transport have been proposed. However, while they are noteworthy, 
they are not directly linked to SOD1-ALS. Admittedly, most cases of ALS have more than 
one mutated gene, but the scope of this project is to understand the role of SOD1 mutations 
in isolation. 
 
Transgenic mouse models carrying mutant versions of SOD1 and other ALS genes display 
cytoplasmic inclusions, mitochondrial dysfunction and motor neuron degeneration similar 
to that of ALS, and have provided insights to the pathogenesis of the disease, but have 
failed to predict therapeutic efficacy in humans. Upregulating protein quality control seems 
to be an ideal strategy for tackling SOD1 inclusions. 
 
Protein quality control refers to the systems cells use to either correctly refold, sequester 
or degrade abnormal proteins. Under normal conditions, the cells tackle misfolded proteins 
originating from improper biogenesis, expressed mutant proteins, unassembled subunits of 
oligomeric proteins and mistranslocated secretory proteins. In addition to these normal 
sources of misfolded proteins, several pathological conditions such as neurodegenerative 
diseases and cancer produce a multitude of such variants. While the cell attempts to refold 
misfolded proteins in most cases, the insurmountable level of proteotoxic stress in SOD1-





Targeting protein quality control has been a common strategy to treat ALS. However, 
several attempts at doing so have failed. Lethal (3) malignant brain tumor like protein 1 
(L3MBTL1) and Sirtulin1 (Sirt1) are targets which have not previously been explored for 
therapeutic potential. Their inhibition serves to increase activity at the p53 promoter, 
ultimately upregulating protein quality control, a strategy that has recently been explored 
for its therapeutic potential in models of neurodegenerative disease (Merlo et al., 2014) . 






Materials and Methods 
Cell Based Assays 
UNC669 Stock Solution 
UNC669 (Abcam) was dissolved in an appropriate amount of DMSO to yield a 200 mM 
solution. This solution was placed in tinted polypropylene centrifuge tubes and stored at -
80 °C for up to two months as per the manufacturer’s instructions. 
 
Cell Culture 
HEK293T cells (ATCC) were grown in Dulbeccos’ Modified Eagle’s Medium (DMEM) 
(Gibco) supplemented with 10% Fetal Bovine Serum (Sigma Aldrich) and 1U Penicillin/1 




HEK293T cells were seeded in six 60 mm culture dishes at a density of 400,000 cells per 
dish. After 24 hours, cells from five out of six dishes were transfected with 150 ng of BOS-
SOD1G85R plasmid using 3 µl of JetPRIME reagent (Polyplus) and 200 µl of JetPRIME 
buffer (Polyplus) as per the manufacturer’s instructions. 
 
UNC669 Treatment and Cell Harvest 
24 hours post transfection, the culture media was aspirated and replaced with 4 mL of 
DMEM. UNC669 dissolved in DMSO was added to the transfected wells with a total 




Following 24 hours of treatment, the media was aspirated and replaced by 220 µL of a lysis 
buffer containing 5% IGEPAL-630, 1x Protease Inhibitor Cocktail (Sigma Aldrich) and 
0.25 mM Iodoacetamide (Sigma Aldrich). Cells were incubated on ice with the lysis buffer 
for three minutes, following which they were scraped off the wells. The lysates obtained 
were individually collected in polypropylene centrifuge tubes and sonicated for two 
intervals of five minutes each at 4°C on high settings (30 seconds on, 30 seconds off). 
Sonicated lysates were stored at -80 °C until further use. 
 
Fractionation 
Sonicated lysates were thawed on ice and transferred to air-driven ultracentrifuge tubes 
(Beckman Coulter). The lysates were centrifuged at ambient temperature using an Airfuge 
Air-Driven Ultracentrifuge (10 minutes, 25,000 psi) (Beckman Coulter). The supernatant 
was collected in fresh centrifuge tubes and labelled as S1 fractions. The pellet was washed 
using a buffer containing 5 M IGEPAL-630, and resuspended in 110 µL of a buffer 
containing 5% SDS, 8 M Urea, 0.1 mM EDTA and 40 mM Tris-Cl ph 6.8. Resuspended 
pellets were sonicated at 15-20 °C for six intervals of five minutes each on high settings 
(30 seconds on, 30 seconds off). Upon sonication, the lysates were labelled as the P2 
fractions. Lysates were stored at -80 °C until further use. Protein concentration in the 
lysates was determined by the BCA assay (Thermo Fisher). 
 
Western Blot 
S1 and P2 samples were aliquoted in 6x SDS sample loading buffer containing 0.375M 




15 µg of protein per sample. Samples were placed in a heating block at 95 °C for five 
minutes, following which they were centrifuged at ambient temperature for three minutes 
at 12,000 rpm. Protein lysates were resolved by SDS-PAGE on 4-20% Criterion TGX 
precast SDS gels (BioRad) at 100V. Upon resolution, proteins were transferred to 
nitrocellulose membranes using the semi-dry Transblot system (BioRad). Membranes were 
incubated in blocking buffer containing 5% non-fat dry milk (Sigma Aldrich) in TBS-T 
(20 mM Tris, 150 mM NaCl, pH7.6, 0.1% Tween®20) on a shaker for two hours. 
Membranes were washed thrice x five min each with TBS-T following overnight 
incubation with primary antibodies [1:3000 polyclonal SOD rabbit (Enzo Life Sciences) 
and 1:2000 ß-Actin clone 4, mouse (SantaCruz Biotech)] in TBS-T containing 5% Bovine 
Serum Albumin (Sigma Aldrich). The membranes were washed thrice x 5 min each with 
5% TBS-T, and incubated with secondary antibody [1:10000 IRDye Anti-mouse IgG 
linked with 680RD (Licor) and 1:1000 IRDye Anti-rabbit IgG linked with 800LT (Licor)] 
on a shaker at room temperature for one hour. The membrane was washed thrice x 5 
minutes each with TBS-T, and imaged on a Licor Odessey imager at 700 nm and 800 nm 
and quantified using ImageStudio. 
 
Animal Based Assays 
Animal Housing and Selection of Experimental Animals 
B6.Cg-Tg(SOD1*G93A)1Gur/J males as well as C57BL/6J females were obtained from 
the Jackson Laboratory. Breeding cages were set up with one male and two females. 
Animals were housed in the institutional animal facility (12 hours white light, 12 hours red 




approved by the institutional animal care and use committee (IACUC). Mice were 
genotyped using PCR, followed by qPCR for analysis of SOD1G93A copy number 
variations. Only gender matched littermates which had a high copy number (>23) were 
selected for experimentation. For PCR genotyping, oIMR0113 (CAT CAG CCC TAA 
TCC ATC TGA) and oIMR0114 (CGC GAC TAA CAA TCA AAG TGA) were used to 
amplify the SOD1G93A transgene, while oIMR7338 (CTA GGC CAC AGA ATT GAA 
AGA TCT) and oIMR7339 (GTA GGT GGA AAT TCT AGC ATC ATC C) served as 
internal positive controls. Upon amplification, the products were electrophoresed on a 
1.5% agarose gel at 90V and subsequently imaged on a UV transilluminator. For copy 
number analysis, oIMR1544 (CAC GTG GGC TCC AGC ATT) and oIMR3580 (TCA 
CCA GTC ATT TCT GCC TTT G) served as internal positive controls while oIMR9665 
(GGG AAG CTG TTG TCC CAA G) and oIMR9666 (CAA GGG GAG GTA AAA GAG 
AGC) were used to amplify SOD1G93A. All reactions were performed as per the instructions 
provided by the Jackson Laboratory. 
 
Euthanasia 
The humane end point of the experiment was when a mouse could not right itself after 
being placed on its back for 30 seconds. At this point, mice were euthanized in an enclosed 









UNC669 (Abcam) was dissolved in an appropriate amount of DMSO and diluted with 
Dulbecco’s Phosphate Buffered Saline (DPBS) (Gibco) to yield a 10 mM and 30 mM 
solution containing 10% DMSO (v/v). The solution was aliquoted in tinted vials at -20 °C 
for up to two months. Tenovin-6 (Adooq Biosciences) was dissolved in an appropriate 
amount of DMSO and diluted with Dulbecco’s Phosphate Buffered Saline (DPBS) (Gibco) 
to yield a 4.5 mM solution containing 10% DMSO (v/v). The solution was aliquoted in 
tinted vials at -20 °C for up to two months. A blank vehicle mix was prepared and stored 
at 4 °C for up to two months. Gender and litter-matched transgenic pairs of mice aged 35 
days were injected with either UNC669 (10 mM or 30 mM), Tenovin-6 4.5 mM or vehicle 
(10% DMSO dissolved in DPBS (Gibco)) intra-peritoneally (I.P.) at 5 mL/kg mouse. The 
injections were subsequently repeated every five days. 
 
Rotarod Assay 
Experimental mice were trained on the Rotarod apparatus (4-32 rpm over 5 minutes) 
(Harvard Apparatus) at the age of 36 days, and subsequently every week. Mice were given 
three attempts, after which they were returned to their cages. Experimental mice were 
tested a day after training. The time taken for mice to fall off the rotarod was noted. Data 
was collected for 16 weeks in triplicates and mice were given 1 minute to recover before 
each trial. The assay was performed on a weekly basis. Both training and testing were 








Body weight measurements were taken on a weekly basis prior to conducting the rotarod 
assay. 
 
Grip Strength Assay 
The strength of all four limbs in combination of experimental mice was assayed using the 
grip strength apparatus (Bioseb) in triplicates. Mice were placed on a perforated grill and 
pulled off it at an angle parallel to the workspace. Data was collected on the highest setting, 




Experimental animals were monitored daily for survival analysis. The humane end point 
was considered the point at which the mouse cannot right itself within 30 seconds of being 
placed on its side, and the age of the mouse was recorded when it reached this phenotype 
following euthanasia as per IACUC guidelines. 
 
Tissue Harvest, Lysate Preparation and Western Blot 
Experimental mice were euthanized at the age of 150 days using a CO2 chamber as per 
IACUC guidelines. The mice were dissected, and organs were harvested in polypropylene 
centrifuge tubes followed by snap freezing them in liquid nitrogen. All harvested organs 




the volume of a lysis buffer containing 5% IGEPAL-630, 1x Protease Inhibitor Cocktail 
(Sigma Aldrich), and 0.25 mM Iodoacetamide (Sigma Aldrich) on ice. Subsequent steps 
of lysate preparation, fractionation and western blotting were carried out with the same 
method used for cell culture. 
 
Mass Spectrometry 
Preparation of standard and internal standard (IS) stock solution 
UNC669 was dissolved in an appropriate amount of DMSO to yield a 10 mM stock 
solution, which was stored in tinted tubes at -20°C. Similarly, Tenovin-6 was dissolved in 
DMSO to yield a 10 mM stock solution and subsequently stored at -20°C. Losartan (IS) 
was dissolved in DMSO to obtain a 10 mM stock solution. This was subsequently diluted 
to obtain a 500 nM solution which was stored at -20°C. 
 
Standard Curve and Quality Control (QC) Sample Preparation 
Standard curve plasma samples were prepared using naïve mouse plasma or naïve mouse 
brain homogenates. Standard curves for both these fractions were prepared by serially 
diluting the stock solution, with 7 standards and 3 QCs ranging from 10 to 10,000 nM in 
mouse plasma and in mouse brain homogenate matrix for UNC669 and 7 standards and 4 
QCs ranging from 50 to 50,000 nM in mouse plasma and 6 standards and 2 QCs from 5 to 








Plasma: UNC669 was extracted from plasma samples by precipitating proteins using 
acetonitrile. Briefly standards, QCs, and samples (50 µL) were mixed with 300 µL 
acetonitrile containing 0.5 µL Losartan (IS) in low retention microcentrifuge tubes. The 
mixtures were vortexed for 1 min and subsequently centrifuged at 10,000 rpm for 10 min 
at 4°C (Eppendorf 5417R). 50 µL of the supernatant was transferred to a 250 µL 
polypropylene autosampler vial and mixed with 50 µL of water, and sealed with a Teflon 
cap. A volume of 3 µL was injected onto the ultra high performance liquid chromatography 
(UHPLC) instrument (Accela pump 1250 and Accela autosampler AS, Thermo Scientific) 
for quantitative analysis using a temperature controlled autosampler operating at 10°C. 
Tenovin-6 was extracted from plasma samples by protein precipitation using acetonitrile. 
Briefly standards, QCs, and samples (25 μL) were mixed with 125 μL acetonitrile 
containing 0.5 μM Losartan (internal standard; IS) in low retention microcentrifuge tubes. 
The mixture was vortexed for 1 min and centrifuged at 10,000 rpm for 10 min at 4°C. 50 
μL of supernatant was transferred to a 250 μL polypropylene autosampler vials and mixed 
with 50 μL water, and sealed with a Teflon cap. A volume of 3 μL was injected onto the 
ultra-performance liquid chromatography (UPLC) instrument for quantitative analysis 
using a temperature-controlled autosampler operating at 10 °C. 
Brain and Spinal Cord: For analysis of tissue samples, standard curve and quality control 
samples were prepared using the brain matrix. For extraction of UNC669, brain and spinal 
cord samples were weighed and extracted with two times the volume of acetonitrile. 
Samples were subsequently placed in -20°C for 30 min and pulverized, followed by 




transferred to a 250 µL polypropylene autosampler vial and was mixed with water 
containing 20 µM Losartan, and sealed with a Teflon cap. A volume of 3 µL was injected 
onto the ultra high performance liquid chromatography (UHPLC) instrument (Accela 
pump 1250 and Accela autosampler AS, Thermo Scientific) for quantitative analysis using 
a temperature controlled autosampler operating at 10°C. 
For analysis of tissue samples, standard curve and quality control samples were prepared 
using brain matrix. For extraction of Tenovin-6, spinal cord and brain samples were 
weighed, and extracted with two times the volume of acetonitrile. Samples were placed in 
-20°C for 30 min and pulverized, followed by vortexing and centrifugation 10,000 rpm at 
4°C for 10 minutes. 50 μL of supernatant was transferred to a 250 μL polypropylene 
autosampler vials and was mixed with 50 μL water with 0.05 μM Losartan, and sealed with 
a Teflon cap. A volume of 3 μL was injected onto the ultra-performance liquid 
chromatography (UPLC) instrument for quantitative analysis using a temperature-
controlled autosampler operating at 10°C.  
 
Chromatographic and Mass Spectrometric Conditions 
UNC669: 
UHPLC System: Accela pump 1250 and Accela open-arm autosampler AS 
Column: Eclipse Plus C18 RRHD 1.8 µm, 2.1 x 100 mm 
Flow Rate: 0.4 mL/min 
Mobile Phase A: 0.1% FA in CAN 





LC Gradient Condition: 
Time (min) Phase A (%) Phase B (%) 
0.01 10 90 
0.20 10 90 
2.00 99 1 
2.50 99 1 
2.70 10 90 





UHPLC System: Accela pump 1250 and Accela open-arm autosampler AS 
Columns: Xterra MS C18 3.5 μm, 2.1x50 mm 
Flow rate: 0.4 mL/min 
Mobile Phase A: 0.1% FA in ACN,  
Phase B: 0.1% FA in water.  
LC Gradient Condition: 
Time (min) Phase A (%) Phase B (%) 
0.01 5 95 
0.20 5 95 
2.00 99 1 
2.50 99 1 




2.70 5 95 
4.50 5 95 
Mass Spectrometry Conditions  




ESI, MRM (+) 
Compound Q1 Q3 CE S-Lens 
UNC669 337.887 155.913, 
183.920 
47, 30 96 
Losartan 423.200 180.088, 
207.107 
35, 22 99 
 
 
The mass spectrometer was operated with an ESI interface with positive ionization mode 
for UNC669 and controlled by the Xcalibur software 2.3 (Thermo Scientific). Samples 
were introduced to the interface through Turbo Ion Spray with the capillary temperature 
setting at 350°C. Nitrogen was used as the sheath and auxiliary gas with settings of 40 and 




Table 2: Liquid chromatography gradient conditions for Tenovin-6 







ESI, MRM (+) 
Compound Q1 Q3 CE S-Lens 
Tenovin-6 494.975 233.027, 
278.115 
30, 19 102 
Losartan 422.860 180.090, 
207.113 
32, 18 89 
 
 
The mass spectrometer was operated with an ESI interface in positive ionization mode for 
Tenovin-6 and controlled by the Xcalibur software 2.3 (Thermo Scientific). Samples were 
introduced to the interface through Turbo Ion Spray with the capillary temperature setting 
at 350°C. Nitrogen was used as the sheath and auxiliary gas with the settings of 40 and 5, 
respectively. Quantification was performed in multiple-reaction monitoring (MRM) mode. 
Chromatographic analysis was performed using an AccelaTM ultra high-performance 
system consisting of an analytical pump, and an autosampler coupled with TSQ Vantage 
mass spectrometer (Thermo Fisher Scientific Inc., Waltham MA). Separation of the analyte 
from plasma, brain and spinal cord matrices was achieved at ambient temperature using a 
Waters Xterra MS C18 (2.1 x 50 mm) packed with a 3.5 μm C18 stationary phase. The 
mobile phase used was composed of 0.1% Formic Acid in Acetonitrile and 0.1% Formic 
Acid in water with gradient elution, starting with 5 % organic linearly increasing to 99% 
at 2 min, maintaining at 99% (2-2.5 min), re-equilibrating to 5 % by 2.7 min and 




maintaining 5 % organic until the end of the run. The total run time for each analyte was 
4.50 min.  
Data were acquired by Xcalibur software. Chromatographic peaks for analyte transitions 
were integrated and quantified to calculate the concentration of each peak based on the 
calibration curve. Calibration curves for Tenovin-6 were computed using the ratio of the 
peak area of analyte to the internal standard by using a quadratic regression with 1/x 
weighting. The parameters of each calibration curve were used to back-calculate 







UNC669 shows rapid penetration and clearance from tissues 
Several compounds have been assessed for their efficacy to treat ALS(Jiang et al., 2014; 
Mancuso et al., 2012; Mancuso et al., 2014; Traynor et al., 2006). However, only Riluzole 
has been approved by the FDA for treatment(Bruijn, Miller, & Cleveland, 2004; 
Lacomblez, 1996) . Although these compounds may be delivered in several ways, their 
distribution across the central nervous system is of immense importance(Bryson & Bryson, 
1996; Prathyusha Vikram, 2017) . UNC669 has been recently characterized an L3MBTL1 
inhibitor(Herold et al., 2012; Zhou et al., 2016)  and has not been used in animal models 
for therapeutic applications. To assess the optimum dosage, we injected mice with a 
standard pharmacokinetic dose (10 mg/kg and 5 mL/kg, which equated to 100 µL of a 10 
mM solution delivered to a 20g mouse) and analyzed its distribution in the plasma, brain 
and spinal cord using mass spectrometry over a time course of three hours. 
Mice administered UNC669 intraperitoneally accumulate the compound in the plasma, 
brain and spinal cord within 30 minutes but is significantly cleared in 3 hours (Fig. 1C). At 
30 minutes, the plasma contains 2724 pmol/mL of UNC669. However, the brain and spinal 
cord contains 5308 pmol/g and 3763 pmol/g respectively at the same time point, suggesting 
that UNC669 readily crosses the blood-brain barrier. Greater accumulation of UNC669 in 
the brain and spinal cord than plasma at the 3 hour time point reinforce greater distribution 
of the compound across the blood-brain barrier. While it readily crosses the blood-brain 
barrier, all tissues significantly cleared most of UNC669 after three hours of 




response could not be identified by this experiment. As a result, two doses (10 mM and 30 
mM) were selected for further experimentation. 
 
 
Trends in body weight progression in UNC669 trials 
Body weight is an essential parameter in understanding degeneration through behavioral 
experiments. The onset of ALS involves rapid degeneration of motor neurons, which 
results in non-recoverable weight loss. Our C57BL/6J mice containing the SOD1G93A 
transgene that go on to develop ALS also show such patterns.  
Fig. 1: (A) Standard curves for UNC669 in plasma (above) and brain (below) with (B) 
a representative chromatogram peak for UNC669. Losartan served as an internal 
control. (C) Concentration of UNC669 in plasma (left), brain (middle) and spinal cord 




Both the treated and untreated groups of mice begin to show a loss in weight at an age of 
19 weeks in the UNC669 10 mM trial (Fig. 2A). Although the vehicle injected mice appear 
to weigh slightly more than UNC669 10 mM treated mice, the difference is not significant. 
The same trend was observed in both groups (Fig. 2A). 
Concurrent with the findings above, the UNC669 30 mM trial showed similar trends with 
the average age of non-recoverable weight loss at 18 weeks (Fig. 3A). Furthermore, there 









Fig. 2: SOD1G93A mice treated with 10 mM UNC669 showed (A) similar trends in 
body weight but (B) exhibited a greater latency to fall off the rotarod as compared to 
the vehicle treated group. (C) UNC669 treatment did not have an effect on the life 
span. (D) The median maximum speed attained by UNC669 treated mice was 
significantly greater than the vehicle group at ages of 12 and 14 weeks, while there 
was no difference between the groups at ages of 20 and 21 weeks. (E) Western blots 
of UNC669 10 mM trial brain tissue show significantly less SOD1G93A in the P2 
fraction. A similar trend was observed in (F) HEK293T cells transfected with 




UNC669 does not improve grip strength 
Neuromuscular strength has been shown to decrease with disease onset due to degeneration 
of motor neurons(Knippenberg, Thau, Dengler, & Petri, 2010; Smittkamp, Brown, & 
Stanford, 2008; Wilson, Petrik, Moghadasian, & Shaw, 2005) . To see if there was a 
difference in muscular strength in mice that have been treated with UNC669 vs their 
untreated counterparts, forelimb strength was chosen as a parameter.  There was no 
observable difference between the test and treated groups of mice (data not shown). 
However, at the age of 12 weeks there seemed to be an increased difference between the 
test and treated groups, with vehicle showing slightly increased forelimb strength (data not 
shown). When mice were dosed with 30 mM of UNC669, there was no observable 
difference between the test and treated mice through the course of the experiment (Fig. 
3B). 
 
UNC669 improves locomotor ability in mice subjected to a 10 mM solution 
Muscular activity is an essential parameter for assessing paralysis caused by ALS. While 
mild paralysis begins slightly before the onset of disease, muscular activity of hind limbs 
exponentially decreases as the disease progresses(Knippenberg et al., 2010; Wilson et al., 
2005) . To test for change in muscular activity, mice were placed on a rotarod, which is an 
accelerating rod that enables assessment of reduced locomotive abilities. As locomotor 
activity reduces, mice lose the ability to stay on the rod for longer periods of time. Hence, 
shorter time on the rotarod hints at reduced muscular activity and hence possible increased 




Mice administered a 10 mM solution of UNC669 performed significantly better in the 
rotarod assay than the control (Fig. 2C). Treated mice were able to stay on the rod for a 
longer period of time than the untreated group from 11 weeks of age up to the point they 
met the euthanasia criteria. It was noted that the difference in locomotor ability, which can 
be read as a latency to fall off the rod, between the treated and untreated mice varied with 
time. The biggest difference between the groups was observed at an age of 12 weeks. 
However, the difference in latency to fall diminished with an increase in time, suggesting 
an age-dependent response to the drug. A possible reason for the age-dependent response 
is a threshold for UNC669 mediated protein quality control, beyond which the misfolding 
stress is too high. In contrast, mice treated with a 30 mM solution of UNC669 did not 
perform better than the vehicle at any point (Fig. 3C).  
 
UNC669 10 mM treatment did not increase the life span of mice 
Survival curves are essential to determine if a test compound has the therapeutic effect to 
increase lifespan. The behavioral end point used was the day at which a mouse cannot right 
itself after 30 seconds of turning it on its back, as used in several other studies. While it is 
well recognized that female SOD1G93A mice live up to a week longer than their male 
counterparts, both males and females were used in the study and they were not analyzed 
separately. 
The UNC669 10 mM treated group median life span was one day greater than that of the 
vehicle, but the difference was not statistically significant (Fig. 2D). Similarly, the 





UNC669 10 mM treated mice run faster than vehicle treated mice 
Locomotor activity can also be studied by the speed at which mice can travel on the rotarod. 
The speed (in rpm) at which mice fell off the rotarod was noted, and converted to mm/s 
using the formula v = r × ω x 1000. The median values were compared between treated 
and untreated groups at several time points. 
The median speed at which mice fell off the rotarod was found to be significantly higher 
in the UNC669 treated group than the vehicle at 12 weeks and 14 weeks of age (Fig. 2E). 
However, there was no difference between the two groups at the end of the trial at 20 weeks 
and 21 weeks respectively (Fig. 2E). 
 
UNC669 treatment did no alter the age of onset 
Disease onset was analyzed by observing gait, ability to walk and the righting reflex while 
scoring it from 1-5 on a modified Neurological Scoring System(Hatzipetros et al., 2015) . 
A score of 1 suggests that the mouse is pre-symptomatic while a score of 5 suggests that 
the mouse has reached its humane end point. 
The median amount of time for mice to reach stage 5 was found to be identical for both 10 
mM and 30 mM UNC669 treatment groups as well as their controls (data not shown). 
However, it was noticed on random occasion that some mice meet the euthanasia 
requirements only a day after reaching stage 5, while others could endure for over a week. 








Fig. 3: Mice treated with UNC669 30 mM show no significant differences 
from vehicle groups in (A) body weight, (B) grip strength, (C) locomotor 




UNC669 reduces the amount of aggregates in vitro and in vivo 
Evidence highlights a toxic gain-of-function mechanism of disease for mutant SOD1 linked 
ALS(Bruijn et al., 2004; Kiernan et al., 2011) . SOD1 aggregates serve to be the pathogenic 
determinant for disease(Bruijn et al., 1998; Kiernan et al., 2011; Watanabe et al., 2001) . 
The G93A mutation does not compromise the enzymatic activity of SOD1 even in 
aggregates(Scott et al., 2008). While SOD1 knockout models obviously show aspects of 
disease, some of which are related to motor neurons, but conclusive evidence linking SOD1 
loss-of-function to ALS does not exist(Rachele A Saccon, Rosie K A Bunton-Stasyshyn, 
Elizabeth M C Fisher, & Pietro Fratta, 2013) . 
To understand the effects of UNC669 on SOD1 aggregates, we used an assay to separate 
small aggregates (S1 fraction) from large aggregates (P2 fractions) based on their 
solubility. 
A dose-dependent response was observed on transfecting HEK293T cells with SOD1G85R 
and treating them with UNC669. While the fraction containing soluble aggregates 
remained unchanged over all concentrations, there was a reduction in larger insoluble 
aggregates at concentrations of 50 µM, 100 µM and 200 µM (Fig. 2G). A similar trend was 
observed in brains isolated from of UNC669 10 mM treated mice, where the amount of 
large aggregates were 20% less than that of the control (Fig. 2F). The reduction in the 
amount of large aggregates, a highly toxic species, coupled with no effect in soluble 
SOD1G85R/G93A suggests that this may be a mechanism for cells to counteract protein 
misfolding stress. Constant levels of the less toxic soluble species could purport the 





Tenovin-6 shows slower penetration into tissues coupled with saturation kinetics 
Mice administered Tenovin-6 intraperitoneally at a concentration of 10 mg/kg and 5 mL/kg 
of the mouse saturate the brain and spinal cord. While the concentration of Tenovin-6 in 
plasma decreases over 3 hours, the brain and spinal cord levels remain constant (Fig. 4C). 
Interestingly, the spinal cord significantly accumulates less Tenovin-6 at the 1.5 hour time 
point as compared to 0.5 hours and 3 hours, a trend that is not present in the brain. 
Furthermore, spinal cord accumulation is driven in part by direct transmission of 
cerebrospinal fluid (CSF) from the brain. While this experiment cannot determine 
causation for this phenomenon, it is possible that fraction of Tenovin-6 in the brain may be 
largely concentrated in cells which suggest that CSF may be saturated at extremely low 
levels of Tenovin-6. This hypothesis coupled with a faster turnover in the spinal cord than 
the brain may explain the reduction of Tenovin-6 concentration at the 1.5 hour time point. 
 
 
Fig. 4: (A) Standard curves for Tenovin-6 in plasma (above) and brain (below 
tissue) with (B) a representative chromatogram peak for Tenovin-6. Losartan 
served as an internal control. (C) Concentration of Tenovin-6 over in plasma 






Tenovin-6 4.5 mM treated mice weighed less than the vehicle 
While both groups of mice showed similar trends in weight gain and loss, the vehicle group 
had a greater mean body weight than the Tenovin-6 group (Fig. 5A). However, the treated 
group had a greater mean body weight at the end of the trial than the vehicle group. 
 
Tenovin-6 4.5 mM treated mice did not exhibit increased grip strength ability 
Although the Tenovin-6 4.5 mM group showed slightly improved grip strength in the 
middle of the trial, the effect wore of as the trial progressed (Fig. 5B). Furthermore, the 
mean grip strength for both groups was almost identical. Similar trends were observed in 
both groups and no difference between the groups was noted. 
 
Tenovin-6 4.5 mM treated mice show better locomotor activity 
Tenovin-6 4.5 mM treaded mice have a greater average latency to fall of the rotarod when 
all time points are considered(Fig. 5C). However, this difference is not significant towards 








Fig. 5: (A) Tenovin-6 treated mice weighed less than vehicle controls but (B) 
performed the same as them on the grip strength assay. (C) Tenovin-6 treated mice 





Tenoving-6 4.5 mM did not significantly increase the lifespan of mice 
Although the median life span of Tenovin-6 4.5 mM treated mice is 5 days more than that 
of the vehicle group and most Tenovin-6 4.5 mM treated mice met the euthanasia criteria 
after the vehicle, the difference is not significant (Fig. 6D). Both groups showed a similar 
trend. 
 
Tenovin-6 4.5 mM did not delay the age of disease onset 
The median age of onset for both groups was found to be similar. Upon reaching stage 5, 






Protein quality control is essential to ensure cellular homeostasis. Dysregulation of this 
process results in several pathological conditions including ALS which leads to a loss of 
motor neurons. While several genes play a role in disease development in concert, the focus 
of this project was to understand the therapeutic potential of small molecules that assist in 
degrading SOD1 aggregates by upregulating p53 mediated transcription. The common 
mouse model C57BL/6J containing the SOD1G93A transgene was employed for this study. 
The mouse contains at least 23 copies of the transgene inserted into the genome, and 
maintaining the high copy number is essential for disease development(Scott et al., 2008) 
. Reports of copy number loss through homologous recombination resulting in a much later 
onset of disease have been published(Acevedo-Arozena et al., 2011; Alexander et al., 2004; 
Deitch et al., 2014; Scott et al., 2008) . However, the study design ensured that gender and 
litter-matched mice with high copy numbers were selected for experimentation. 
p53 has been shown to be drastically elevated in brain and spinal cord tissue from mice 
and humans suffering from ALS, generating a long-standing hypothesis that immense 
upregulation results in motor neuron apoptosis(Barbosa et al., 2010; Eve, Dennis, & Citron, 
2007; Martin, 2000) . However, a few studies challenged this notion and showed that p53 
upregulation assists with protein quality control in ALS and Alzheimer’s Disease 
models(Merlo et al., 2014; Periz et al., 2015), and that disease development is imminent 
regardless of p53 status(Prudlo et al., 2000) . UNC669 and Tenovin-6, both upregulate p53 
mediated transcription in independent ways. UNC669 promotes recruitment of p53 to its 
promoter via SETD8 by inhibiting the histone-L3MBTL1 interaction(Arrowsmith et al., 




upregulation by inhibiting the protein deacetylases SIRT1/2(James T. Lee & Wei Gu, 
2013; van Leeuwen et al., 2011) . 
This study shows that p53 upregulation benefited neuromuscular activity in mice, which is 
analogous to improving quality of life in humans, but did not delay disease onset or increase 
life span. In addition, UNC669 (Fig. 2F, Fig. 2G) and Tenovin-6 reduced the number of 
large SOD1 aggregates (unpublished data, Goran Periz). 
UNC669 showed a dose and age dependent response in mice (Fig. 2A, Fig. 2B, Fig. 2D, 
Fig. 2E, Fig. 2F, Fig. 3A, Fig. 3B, Fig. 3C). It is interesting to note that mice subjected to 
a 10 mM solution benefited from treatment, while those subjected to a 30 mM solution did 
not. This suggests a possible threshold of p53 activation to observe beneficial physiological 
effects, beyond which the apoptotic machinery is overworked and resulting in cell death. 
While this hypothesis was not examined by the study, immunohistochemical analyses of 
p53 from central nervous system tissue along with co-localization studies may provide 
insights to this interesting phenomenon. Furthermore, mice between the age group of 11-
17 weeks (Fig. 2C) seemed to benefit from treatment the most. While the study examined 
bioavalability of UNC669 to the brain and spinal cord (Fig. 1C), one cannot rule out altered 
bioavailability at different age groups. Mice with ages varying from 6 weeks – 12 weeks 
were selected for mass spectrometry, and it is possible that bioavalability to the central 
nervous system may reduce with age. Furthermore, non-transgenic mice were selected for 
mass spectrometry and it has not been confirmed that the distribution of UNC669 in a non-
transgenic mouse resembles that of SOD1G93A transgenic model. 
Aggregation is a hallmark of SOD1-ALS. Large aggregates are extremely proteotoxic and 




2(Pasinelli et al., 2004) . UNC669 cleared large SOD1 aggregates but not smaller ones in 
vitro and in vivo (Fig. 2F, Fig. 2G) suggesting that a misfolding stress response was coming 
into play. Unperturbed levels of smaller aggregates and soluble SOD1G93A/G85R suggest that 
the effect may not be caused due to decreased transcription of SOD1G93A/G85R but increased 
protein degradation. Indeed, this was confirmed in a cycloheximide chase which showed 
greater degradation on knocking down L3MBTL1 as compared to the control (unpublished 
data, Goran Periz). 
Tenovin-6 has been extensively studied for its role in protein quality control in models of 
neurodegenerative disease and cancer(Brooks & Gu, 2009; Hirai et al., 2014; Lane, Fersht, 
Brown, Verma, & Lain, 2009) . Upon questioning its distribution over time after an 
intraperitoneal injection, the study showed saturation kinetics in the brain and spinal cord. 
However, the concentration of Tenovin-6 in spinal cord samples at the 1.5 hour time point 
was significantly lower than that of the 0.5 hour and 3 hour time point (Fig. 4C). This is 
perplexing and may be dependent on the distribution of Tenovin-6 in cerebrospinal fluid 
and cells in the central nervous system. 
The study showed that Tenovin-6 treated mice had better locomotor activity but lower body 
weight as compared to its control (Fig. 5A, Fig. 5C). This is perplexing as decreased body 
weight may be associated with a greater intensity of disease, while increased 
neuromuscular activity suggests protection from disease. Interestingly, Tenovin-6 
benefited mice the most in the latter stages, suggesting that it is indeed protecting from 
disease. Furthermore, mice treated with Tenovin-6 weighed more than the control group at 





Lastly, these findings suggest that upregulating p53 may be a viable option to treat SOD1-
ALS. Although it does not appear to delay disease onset or prolong lifespan, it has 
prominent effects on aggregation and neuromuscular activity. Since UNC669 and Tenovin-
6 appear to have an age-dependent response in mice, using them in conjunction may be 
fruitful. Indeed, this study has not examined their exact mechanisms of action and future 







Acevedo-Arozena, A., Kalmar, B., Essa, S., Ricketts, T., Joyce, P., Kent, R., . . . Fisher, 
E. M. C. (2011). A comprehensive assessment of the SOD1G93A low-copy 
transgenic mouse, which models human amyotrophic lateral sclerosis. Disease 
Models & Mechanisms, 4(5), 686. doi:10.1242/dmm.007237 
Alexander, G. M., Erwin, K. L., Byers, N., Deitch, J. S., Augelli, B. J., Blankenhorn, E. 
P., & Heiman-Patterson, T. D. (2004). Effect of transgene copy number on survival 
in the G93A SOD1 transgenic mouse model of ALS. Molecular Brain Research, 
130(1), 7-15. doi:10.1016/j.molbrainres.2004.07.002 
Arrowsmith, C. H., Nady, N., Allali-Hassani, A., Liu, Y., Qi, C., MacKenzie, F., . . . 
Ouyang, H. (2007). L3MBTL1 recognition of mono- and dimethylated histones. 
Nature Structural & Molecular Biology, 14(12), 1229-1230. doi:10.1038/nsmb1340 
Barbosa, L. F., Cerqueira, F. M., Macedo, A. F. A., Garcia, C. C. M., Angeli, J. P. F., 
Schumacher, R. I., . . . Medeiros, M. H. G. (2010). Increased SOD1 association with 
chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-
linked ALS. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease, 
1802(5), 462-471. doi:10.1016/j.bbadis.2010.01.011 
Brooks, C. L., & Gu, W. (2009). Perspectives. London: s.n. Retrieved from 
http://www.nature.com.ezp.welch.jhmi.edu.proxy1.library.jhu.edu/nrc/journal/v9/n2/
full/nrc2562.html  
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., 




linked SOD1 mutant independent from wild-type SOD1. Science, 281(5384), 1851-
1854. Retrieved from http://www.jstor.org/stable/2895798 
Bruijn, L. I., Miller, T. M., & Cleveland, D. W. (2004). Unraveling the mechanisms 
involved in motor neuron degradation in ALS. 
Http://Dx.Doi.Org.Ezp.Welch.Jhmi.Edu/10.1146/Annurev.Neuro.27.070203.144244, 
27, 723-749. doi:10.1146/annurev.neuro.27.070203.144244 
Bryson, H. M., & Bryson, H. M. (1996). A review of its pharmacodynamic and 
pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. 
Drugs, 52(4), 549-563.  
Corcia, P., Couratier, P., Blasco, H., Andres, C. R., Beltran, S., Meininger, V., & Vourc’h, 
P. (2017). Genetics of amyotrophic lateral sclerosis. Revue Neurologique, 173(5), 254-
262. doi:10.1016/j.neurol.2017.03.030 
Deitch, J. S., Alexander, G. M., Bensinger, A., Yang, S., Jiang, J. T., & Heiman-
Patterson, T. D. (2014). Phenotype of transgenic mice carrying a very low copy 
number of the mutant human G93A superoxide dismutase-1 gene associated with 
amyotrophic lateral sclerosis. PLoS ONE, 9(6), 1-6. 
doi:10.1371/journal.pone.0099879 
Eve, D. J., Dennis, J. S., & Citron, B. A. (2007). Transcription factor p53 in degenerating 
spinal cords. Brain Research, 1150, 174-181. doi:10.1016/j.brainres.2007.02.088 
Hatzipetros, T., Kidd, J. D., Moreno, A. J., Thompson, K., Gill, A., & Vieira, F. G. 
(2015). A quick phenotypic neurological scoring system for evaluating disease 
progression in the SOD1-G93A mouse model of ALS. Journal of Visualized 




Herold, J. M., James, L. I., Korboukh, V. K., Gao, C., Coil, K. E., Bua, D. J., . . . Frye, S. 
V. (2012). Structure–activity relationships of methyl-lysine reader antagonists. Med. 
Chem. Commun, 3(1), 45-51. doi:10.1039/C1MD00195G 
Hirai, S., Endo, S., Saito, R., Hirose, M., Ueno, T., Suzuki, H., . . . Hyodo, I. (2014). 
Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via 
death receptor 5 up-regulation. PLoS ONE, 9(7), 1-10. 
doi:10.1371/journal.pone.0102831 
James T. Lee, & Wei Gu. (2013). SIRT1: Regulator of p53 deacetylation reprints and 
permission: SAGE Publications. doi:10.1177/1947601913484496 
Jiang, H. -., Ren, M., Jiang, H. -., Wang, J., Zhang, J., Yin, X., . . . Feng, H. -. (2014). 
Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor 
performance and attenuates motor neuron loss in the SOD1 G93A mouse model of 
amyotrophic lateral sclerosis. Neuroscience, 277, 132-138. 
doi:10.1016/j.neuroscience.2014.03.047 
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., . . . Zoing, 
M. C. (2011). Amyotrophic lateral sclerosis. The Lancet, 377(9769), 942-955. 
doi:10.1016/S0140-6736(10)61156-7 
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., . . . 
Zoing, M. C. (2011). Amyotrophic lateral sclerosis. The Lancet, 377(9769), 942-955. 
doi:10.1016/S0140-6736(10)61156-7 
Klara Acs, Martijn S Luijsterburg, Leena Ackermann, Florian A Salomons, Thorsten 




recruitment by removing L3MBTL1 from DNA double-strand breaks. Nature 
Structural & Molecular Biology, 18(12), 1345-1350. doi:10.1038/nsmb.2188 
Knippenberg, S., Thau, N., Dengler, R., & Petri, S. (2010). Significance of behavioural 
tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). 
Behavioural Brain Research, 213(1), 82-87. doi:10.1016/j.bbr.2010.04.042 
Lacomblez, L. (1996). Dose-ranging study of riluzole in amyotrophic lateral sclerosis. 
Lancet, 347(9013), 1425-1431.  
Lane, D. P., Fersht, A. R., Brown, C. J., Verma, C. S., & Lain, S. (2009). Awakening 
guardian angels: Drugging the p53 pathway. Nature Reviews Cancer, 9(12), 862-873. 
doi:10.1038/nrc2763 
Mancuso, R., Oliván, S., Rando, A., Casas, C., Osta, R., & Navarro, X. (2012). Sigma-1R 
agonist improves motor function and motoneuron survival in ALS mice. 
Neurotherapeutics: The Journal of the American Society for Experimental 
NeuroTherapeutics, 9(4), 814-826. doi:10.1007/s13311-012-0140-y 
Mancuso, R., Valle, J. d., Modol, L., Martinez, A., Granado-Serrano, A. B., Ramirez-
Núñez, O., . . . Navarro, X. (2014). Resveratrol improves motoneuron function and 
extends survival in SOD1G93A ALS mice. Neurotherapeutics, 11(2), 419. 
doi:10.1007/s13311-013-0253-y 
Martin, L. J. (2000). p53 is abnormally elevated and active in the CNS of patients with 
amyotrophic lateral sclerosis. Neurobiology of Disease, 7(6), 613-622. 
doi:10.1006/nbdi.2000.0314 
Merlo, P., Frost, B., Peng, S., Yang, Y. J., Park, P. J., & Feany, M. (2014). P53 prevents 




Academy of Sciences of the United States of America, 111(50), 18055. 
doi:10.1073/pnas.1419083111 
Pasinelli, P., Belford, M. E., Lennon, N., Bacskai, B. J., Hyman, B. T., Trotti, D., & 
Brown, R. H. (2004). Amyotrophic lateral sclerosis-associated SOD1 mutant proteins 
bind and aggregate with bcl-2 in spinal cord mitochondria. Neuron, 43(1), 19-30. 
doi:10.1016/j.neuron.2004.06.021 
Periz, G., Lu, J., Zhang, T., Kankel, M. W., Jablonski, A. M., Kalb, R., . . . Wang, J. 
(2015). Regulation of protein quality control by UBE4B and LSD1 through p53-
mediated transcription. PLoS Biology, 13(4) doi:10.1371/journal.pbio.1002114 
Prathyusha Vikram, P., Shanmugasundaram. (2017). Determination of riluzole in human 
plasma by ultra performance liquid chromatography - tandem mass spectrometry 
(UPLC - MS/MS) and its application to a pharmacokinetic study.10(1), 193-199. 
Retrieved from https://search-proquest-
com.ezp.welch.jhmi.edu/docview/1875652183?accountid=11752 
Prudlo, J., Koenig, J., Gräser, J., Burckhardt, E., Mestres, P., Menger, M., & Roemer, K. 
(2000). Motor neuron cell death in a mouse model of FALS is not mediated by the 
p53 cell survival regulator. Brain Research, 879(1), 183-187. doi:10.1016/S0006-
8993(00)02745-1 
Rachele A Saccon, Rosie K A Bunton-Stasyshyn, Elizabeth M C Fisher, & Pietro Fratta. 
(2013). Is SOD1 loss of function involved in amyotrophic lateral sclerosis?. England: 
doi:10.1093/brain/awt097 
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., . . . 




with familial amyotrophic lateral sclerosis Nature Publishing Group. 
doi:10.1038/362059a0 
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., . . . Heywood, 
J. A. (2008). Design, power, and interpretation of studies in the standard murine 
model of ALS. Amyotrophic Lateral Sclerosis, 9(1), 4-15. 
doi:10.1080/17482960701856300 
Smittkamp, S. E., Brown, J. W., & Stanford, J. A. (2008). Time-course and 
characterization of orolingual motor deficits in B6SJL-tg(SOD1-G93A)1Gur/J mice. 
Neuroscience, 151(2), 613-621. doi:10.1016/j.neuroscience.2007.10.017 
Talbott, E. O., Malek, A. M., & Lacomis, D. (2016). The epidemiology of amyotrophic 
lateral sclerosis doi:10.1016/B978-0-12-802973-2.00013-6 
Traynor, B. J., Bruijn, L., Conwit, R., Beal, F., O’Neill, G., Fagan, S. C., & Cudkowicz, 
M. E. (2006). Neuroprotective agents for clinical trials in ALS A systematic 
assessment. Neurology, 67(1), 20-27. doi:10.1212/01.wnl.0000223353.34006.54 
Trojer, P., Li, G., Sims, R. J., Vaquero, A., Kalakonda, N., Boccuni, P., . . . Reinberg, D. 
(2007). L3MBTL1, a histone-methylation-dependent chromatin lock. Cell, 129(5), 
915-928. doi:10.1016/j.cell.2007.03.048 
van Leeuwen, I. M. M., Higgins, M., Campbell, J., Brown, C. J., McCarthy, A. R., Pirrie, 
L., . . . Laín, S. (2011). Mechanism-specific signatures for small-molecule p53 
activators. Cell Cycle, 10(10), 1590-1598. doi:10.4161/cc.10.10.15519 
Watanabe, M., Dykes-Hoberg, M., Cizewski Culotta, V., Price, D. L., Wong, P. C., & 




transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiology of 
Disease, 8(6), 933-941. doi:10.1006/nbdi.2001.0443 
Wilson, J. M. B., Petrik, M. S., Moghadasian, M. H., & Shaw, C. A. (2005). Examining 
the interaction of apo E and neurotoxicity on a murine model of ALS-PDC. 
Canadian Journal of Physiology and Pharmacology, 83(2), 131-141. 
doi:10.1139/y04-140 
Yasuda, K., Clatterbuck-Soper, S. F., Jackrel, M. E., Shorter, J., & Mili, S. (2017). FUS 
inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting 
microtubule detyrosination. The Journal of Cell Biology, 216(4), 1015-1034. 
doi:10.1083/jcb.201608022 
Zhou, H., Che, X., Bao, G., Wang, N., Peng, L., Barnash, K. D., . . . Bai, X. (2016). 
Design, synthesis, and protein methyltransferase activity of a unique set of 
constrained amine containing compounds. Bioorganic & Medicinal Chemistry 






325 East University Parkway 
Baltimore, MD 21218 
(M) +1 470-985-4711 | yshah2@jhmi.edu 
 
EDUCATION 
Master of Science (ScM)                                                                 Expected August 2017 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
Concentration: Biochemistry and Molecular Biology 
Relevant Coursework: Genomics for Public Health, Molecular Toxicology, Cellular Stress in 
Physiology and Disease, Genome Integrity and Cancer, Immunology Infection and Disease, Statistical 
Reasoning in Public Health I, Practical Epidemiology for Basic Scientists 
 
Bachelor of Science (BSc)                                                                                  April 2014 
University of Mumbai, India 
Majors: Biochemistry and Life Sciences 
 
EXPERIENCE 
Graduate Student                                                                                Aug. 2015 – Present 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
• Collected, organized, and compiled data pertaining to a project that studies the 
effect of candidate drugs in preclinical trials conducted in murine models of ALS 
• Conducted extensive in vitro and in vivo studies including drug dosage (IP) and 
tissue harvest for pharmacokinetic studies 
• Evaluated the efficacy of candidate drugs through biochemical and behavioral 
assays in rodent models of ALS as well as mammalian cell lines 
• Optimized PCR genotyping protocols, and gained extensive knowledge of mouse 
genetics, mouse handling, surgery, necropsy, dissection and breeding 
• Assisted with iPSC culture 
 
Clinical Research Assistant                                                                        Mar. – Jul. 2015 
Department of Clinical Research, National Institute for Research in Reproductive Health, 
Mumbai, India  
• Established and standardized PCR protocols 
• Conducted genotyping experiments and analyzed genome sequencing data to 
identify novel polymorphisms in the CFTR gene 
• Assisted with genetic counselling of patients suffering from Congenital Bilateral 
Absence of the Vas Deferens (CBAVD) 
 
Research Assistant                                                                                       May – July 2013 
Department of Biochemistry, National Institute for Research in Reproductive Health, 
Mumbai, India  
• Performed biochemical assays to detect the prevalence of HIV in clinical samples 





Intern                                                                                                             Jan. – June 2011 
Samit Diagnostic Centre, Mumbai, India  
• Assisted a diagnostic laboratory with techniques ranging from PCR, ELISA, 
agarose gel electrophoresis and other biochemical tests 
 
Intern                                                                                                            June – Dec. 2010 
Eyeglobal Technologies Pvt. Ltd., Mumbai, India  
• Assisted in business development, customer relationship management, staffing and 
other operational functions of the human resource management company 
 
Intern                                                                                                  Nov. 2009 – May 2010 
Ronuplate Pvt. Ltd., Mumbai, India  
• Assisted with quality control in an electroplating plant 
 
PUBLICATIONS AND CONFERENCES 
• Langseth, J.A., Kim, J., Ugolino, J., Shah, Y., Hwang, H., Wang, J., Bergles, D., 
Brown, S. (2017). Cell-type specific differences in promoter activity of the ALS-
linked C9orf72 mouse ortholog. Scientific Reports. 
• Presented research “New Players in Protein Quality Control” at the Department of 
Biochemistry and Molecular Biology Retreat (April, 2017) 
• Shah, Y., Rai, S. and Vajpai, A. (2014). Current advances in the use of 
phytochemicals for the treatment of Obesity: A Review. Jigyasa, 10(1), pp.63-69. 
• Individually presented paper entitled “Current advances in the use of 
phytochemicals for the treatment of Obesity: A Review” at the University Grants 
Commission Research Scholars’ Meet (January, 2014) 
 
HONORS AND AWARDS 
• Science Honors (2014) 
 
PROFESSIONAL DEVELOPMENT 
• Mentorship: Mentoring two Masters students (April, 2017 – current) 
• Computer Skills: Microsoft Office Suite, Adobe Illustrator, Adobe Photoshop, 
Adobe Indesign, Graphpad Prism, ImageJ 
• Laboratory Techniques:  
o Molecular Biology: DNA/RNA isolation, PCR, qPCR, SDS-PAGE, 
Agarose Gel Electrophoresis, Western Blot, ELISA (for p24), , Molecular 
cloning, Protein extraction, Protein fractionation 
o Cell Biology: Mammalian cell culture (HEK293T, HeLa, MEF, Vk2/E6E), 
iPSC culture, PBMC isolation, Fluorescence microscopy 
o Animal Models: Surgery, Dissection, Tissue harvest, Necropsy, 
Transcardial perfusion, Drug dosing (IP), Mouse genetics, Animal 
handling, Mouse breeding, Retro-orbital sinus bleeding, Genotyping, 
Behavioral assays 




• Memberships and Leadership Positions:  
o 2016: American Society for Biochemistry and Molecular Biology, JHSPH 
Student Assembly 
o 2015: JHSPH Sustainability Liaison, JHU Indian Graduate Students 
Association 
o 2011: KC College Public Relations Team 
 
  
